A Phase 3 interventional study of Deucravacitinib and Placebo in Sjögren's Syndrome, sponsored by Bristol-Myers Squibb. Active, not recruiting at 199 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.
Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 2nd largest by enrollment of the 76 interventional ones that give a count, is one of 5 that started in 2023, is one of 12 in phase 3, reaches primary completion later than 4 of the 27 other live ones, and was the 88th registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Australia, Austria and 17 more countries
Ages 18+
Vor Biopharma · Sites in United States, Georgia
Ages 18–75
National Institute of Dental and Craniofacial Research (NIDCR) · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 36 · Phase 3 14 · Phase 4 3
First in 1984; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 774 is above the median of 50 across 218 interventional studies indexed under Sjogren's Syndrome.
Median enrollment 57 across the 76 interventional studies, 220 across the 35 observational. Of the 76 that completed or were terminated, 27 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 111 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 4 studies filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Sjogren's Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05946941Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | 2026-11-18 |
| NCT06741969Phase 3Janssen Research & Development, LLCNipocalimab in Moderate to Severe Sjogren's Disease | 2027-02-04 |
| NCT07277257Center For SightEvaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome | 2026-12-31 |
| NCT03276923Duke UniversityMaternal Autoimmune Disease Research Alliance (MADRA) Registry | 2027-01-01 |
| NCT07732582Tufts UniversitySjogren's Mini-Pill Oral and Gut Microbiome Study | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 111 studies in Sjogren's Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Deucravacitinib
Drug: Deucravacitinib
Drug: Deucravacitinib · Other: Placebo
Specified dose on specified days
Also known as: BMS-986165
Specified dose on specified days
Change from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 52
Time frame: Baseline, Week 52
Change from baseline in European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 52
Time frame: Baseline, Week 52
Number of participants with decrease in ESSPRI ≥ 1 or 15% from baseline at Week 52
Time frame: Baseline, Week 52
Number of participants with decrease in ESSDAI ≥ 3 points from baseline at Week 52
Time frame: Baseline, Week 52
Number of participants with ESSDAI < 5 at Week 52
Time frame: Baseline, Week 52
Change from baseline in ESSDAI at Week 24
Time frame: Baseline, Week 24
Change from baseline in stimulated whole salivary flow (SWSF) at Week 52
Time frame: Baseline, Week 52
Change from baseline in physician global assessment (PhGA) at Week 52
Time frame: Baseline, Week 52
Change from baseline in functional assessment of chronic illness therapy (FACIT)-fatigue at Week 52
Time frame: Baseline, Week 52
Change from baseline in ocular dryness numeric rating scale (NRS) at Week 52
Time frame: Baseline, Week 52
Change from baseline in oral dryness NRS at Week 52
Time frame: Baseline, Week 52
Change from baseline in joint/ muscle pain NRS at Week 52
Time frame: Baseline, Week 52
Number of participants with an increase of Schirmer's test ≥ 5 mm if abnormal baseline or no change of Schirmer's test to abnormal if baseline is normal
Time frame: Baseline, Week 52
Number of participants with adverse events (AEs)
Time frame: Up to Week 160
Number of participants with serious AEs (SAEs)
Time frame: Up to Week 160
Number of participants with AEs leading to discontinuation of treatment and study discontinuation
Time frame: Up to Week 160
Number of participants with AEs of special interest (AESIs)
Time frame: Up to Week 160
Number of participants with clinical laboratory abnormalities
Time frame: Up to Week 160
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to Week 156
Number of participants with vital sign abnormalities
Time frame: Up to Week 160
Showing the first 100 of 199 sites across 33 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib